Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug

Oncology Reports

Volumn 32, Issue 2, 2014, Pages 469-474

  Amable, Lauren ^a   Fain, Jason ^b   Gavin, Elaine ^b   Reed, Eddie ^a  

^a NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Cisplatin resistance; Cisplatin transport; DNA adduct; DNA repair; Gli1; Ovarian cancer

Indexed keywords

CISPLATIN; MENKES PROTEIN; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR GLI1; WILSON DISEASE PROTEIN; ANTINEOPLASTIC AGENT; CATION TRANSPORT PROTEIN; GLI1 PROTEIN, HUMAN; ORGANIC CATION TRANSPORTER; SLC31A1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

5' UNTRANSLATED REGION; ARTICLE; ATP7A GENE; ATP7B GENE; BINDING SITE; CELL MEMBRANE RESISTANCE; CONTROLLED STUDY; CTR1 GENE; CTR2 GENE; DNA DAMAGE; DNA REPAIR; DNA SEQUENCE; DRUG ACCUMULATION; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN CELL; IC 50; OCT1 GENE; OCT2 GENE; OCT3 GENE; OVARIAN CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN FUNCTION; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BINDING SITES; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ORGANIC CATION TRANSPORT PROTEINS; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 84903128155     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3257     Document Type: Article

References (32)

1. Kudo K, Gavin E, Das S, Amable L, Shevde LA and Reed E: Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene 31: 4718-4724, 2012.
2. Steg AD, Bevis KS, Katre AA, et al: Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 18: 869-881, 2012.
3. + glioma stem cells to temozolomide therapy. Mol Med 17: 103-112, 2011.
4. Reed E: Cisplatin, carboplatin and oxaliplatin. In: Cancer Chemotherapy and Biotherapy: Principles and Practice. 4th edition. Chabner BA and Longo DL (eds). Lippincott Williams and Wilkins, Philadelphia, pp332-343, 2006.
5. Parker RJ, Eastman A, Bostick-Bruton F and Reed E: Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87: 772-777, 1991.
6. Reed E: Cisplatin and platinum analogs. In: Cancer Principles and Practice of Oncology. 8th edition. DeVita VT, Rosenberg SA and Lawrence T (eds). Lippincott Williams and Wilkins, Philadelphia, pp419-426, 2008.
7. Reed E and Chabner BA: Platinum analogues. In: Cancer Chemotherapy and Biotherapy: Principles and Practice. 5th edition. Chabner BA and Longo DL (eds). Lippincott Williams and Wilkins, Philadelphia, pp310-322, 2011.
8. Hall MD, Okabe M, Shen DW, Liang XJ and Gottesman MM: The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48: 495-535, 2008. (Pubitemid 351738162)
9. Reed E, Sauerhoff S and Poirier MC: Quantitation of platinum- DNA binding in human tissues following therapeutic levels of drug exposure: a novel use of graphite furnace spectrometry. Atomic Spectroscopy 9: 93-95, 1988.
10. Laner-Plamberger S, Kaser A, Paulischta M, Hauser-Kronberger C, Eichberger T and Frischauf AM: Cooperation between GLI and JUN enhances transcription of JUN and selected GLI target genes. Oncogene 28: 1639-1651, 2009.
11. Zhu H and Lo HW: The human glioma-associated oncogene homolog 1 (GLI1) family of transcription factors in gene regulation and diseases. Curr Genomics 11: 238-245, 2010.
12. Hess J, Angel P and Schorpp-Kistner M: AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117: 5965-5973, 2004. (Pubitemid 40123963)
13. Stein B, Angel P, van Dam H, et al: Ultraviolet-radiation induced c-jun gene transcription: two AP-1 like binding sites mediate the response. Photochem Photobiol 55: 409-415, 1992.
14. Lee KB, Parker RJ, Bohr V, Cornelison T and Reed E: Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 14: 2177-2180, 1993. (Pubitemid 23311452)
15. Richon VM, Schulte N and Eastman A: Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res 47: 2056-2061, 1987. (Pubitemid 17074608)
16. Eastman A and Schulte N: Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 27: 4730-4734, 1988.
17. Eastman A: Mechanisms of resistance to cisplatin. Cancer Treat Res 57: 233-249, 1991.
18. Reed E: Cisplatin. In: Cancer Chemotherapy and Biological Response Modifiers. Pinedo H, Longo D and Chabner B (eds). Elsevier Science, Amsterdam, pp83-90, 1992.
19. Dabholkar M, Parker R and Reed E: Determinants of cisplatin sensitivity in non-malignant non-drug-selected human T cell lines. Mutat Res 274: 45-56, 1992.
20. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M and Hamilton TC: Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 48: 5713-5716, 1988.
21. Ferry KV, Hamilton TC and Johnson SW: Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ercc1-xpf. Biochem Pharmacol 60: 1305-1313, 2000.
22. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC and Anderson ME: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074, 1992.
23. Yao KS, Godwin AK, Johnson SW, Ozols RF, O'Dwyer PJ and Hamilton TC: Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 55: 4367-4374, 1995.
24. Agyeman A, Mazumdar T and Houghton JA: Regulation of DNA damage following termination of Hedgehog (HH) survival signaling at the level of the GLI genes in human colon cancer. Oncotarget 3: 854-868, 2012.
25. Leonard JM, Ye H, Wetmore C and Karnitz LM: Sonic Hedgehog signaling impairs ionizing radiation-induced checkpoint activation and induces genomic instability. J Cell Biol 183: 385-391, 2008.
26. Mazumdar T, Devecchio J, Agyeman A, Shi T and Houghton JA: Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells. Cancer Res 71: 5904-5914, 2011.
27. Mazumdar T, DeVecchio J, Agyeman A, Shi T and Houghton JA: The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer. Oncotarget 2: 638-645, 2011.
28. Amable L, Gavin E, Kudo K, et al: Gli1 upregulates c-jun through a specific 130 kDa isoform. Int J Oncol (In press).
29. Martins V, Hanana M, Blumwald E and Geros H: Copper transport and compartmentation in grape cells. Plant Cell Physiol 53: 1866-1880, 2012.
30. Takahashi R, Bashir K, Ishimaru Y, Nishizawa NK and Nakanishi H: The role of heavy-metal ATPases, HMAs, in zinc and cadmium transport in rice. Plant Signal Behav 7: 1605-1607, 2012.
31. Mikkelsen MD, Pedas P, Schiller M, et al: Barley HvHMA1 is a heavy metal pump involved in mobilizing organellar Zn and Cu and plays a role in metal loading into grains. PLoS One 7: e49027, 2012.
32. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F and Reed E: Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 273: 23419-23425, 1998. (Pubitemid 28417531)